12 August 2019 - The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today published advice accepting four new medicines.

Inotersen (Tegsedi) was accepted for the treatment of polyneuropathy (a form of nerve damage) in adults with hereditary transthyretin amyloidosis.

Venetoclax (Venclyxto) was accepted for use in combination with rituximab, in patients who had received at least one previous treatment for chronic lymphocytic leukaemia.

Read SMC press release